CoChat
Sign Up
Cited by 168

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer’s Disease

Small, Scott A., Simoes-Spassov, Sabrina, Mayeux, Richard, Petsko, Gregory A.·2017·Trends in Neurosciences
DOI 10.1016/j.tins.2017.08.003PMC PMC5654621
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tins.2017.08.003

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SORLA has been previously shown to be an important regulator of endolysosomal trafficking, and downregulation of endosomal retromer components has been observed in AD.

    “SORLA has been previously shown to be an important regulator of endolysosomal trafficking, and downregulation of endosomal retromer components has been observed in AD (Small, Simoes-Spassov et al. 2017).”

    From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Small, Simoes-Spassov et al. 2017

    In “Endosomal Traffic Jams Can Occur as an Upstream Event” (page not provided), the paper identifies SORL1/SORLA as involved in trafficking cargo through endosomal pathways. It links retromer alterations to AD-related endosomal dysfunction, but the passages do not report an observed downregulation of retromer components in AD. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Altered endosomal recycling has been implicated in neurodegenerative diseases, including Alzheimer's and Parkinson's disease.

    “Altered endosomal recycling has been implicated in neurodegenerative diseases, including Alzheimer’s (Small et al., 2005; Small et al., 2017) and Parkinson’s disease (Vilariño-Güell et al., 2011; Zimprich et al., 2011; Zavodszky et al., 2014; McGough et al., 2014).”

    From Recruitment of the SNX17-Retriever recycling pathway regulates synaptic function and plasticity (2023) · cites this paper as Small et al., 2017

  • Disruption of retromer-dependent endosomal trafficking is pathogenic in late-onset Alzheimer's disease.

    “Disruption of retromer-dependent endosomal trafficking is considered pathogenic in late-onset Alzheimer’s disease (AD).”

    From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Small et al., 2017

  • Perturbed endosomal transport is a contributing factor and, in some cases, a causative factor in human diseases, including neurodegenerative and neurological, and metabolic syndromes and cardiovascular disease.

    “An increasing body of evidence points to perturbed endosomal transport being a contributing factor and, in some cases, a causative factor in human diseases, including neurodegenerative and neurological2–4, and metabolic syndromes and cardiovascular disease5.”

    From Mapping of endosomal proximity proteomes reveals Retromer as a hub for RAB GTPase regulation (2025) · cites this paper as [3]

  • Functional retrieval sub-domains are essential for development and homeostasis, and disease-associated sub-domain dysregulation is associated with human disease.

    “Analysis in cells and organisms have established the essential importance of functional retrieval sub-domains for development and homeostasis, and disease-associated sub-domain dysregulation is associated with human disease2–5.”

    From Mapping of endosomal proximity proteomes reveals Retromer as a hub for RAB GTPase regulation (2025) · cites this paper as [3]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  2. Guerreiro, 2013, SnapShot: genetics of Alzheimer’s disease, Cell, 155, 10.1016/j.cell.2013.10.037 · DOI
  3. Karch, 2015, Alzheimer’s disease risk genes and mechanisms of disease pathogenesis, Biol. Psychiatry, 77, 43, 10.1016/j.biopsych.2014.05.006 · DOI · Paper page
  4. Naj, 2017, Genomic variants, genes, and pathways of Alzheimer’s disease: an overview, Am. J. Med. Genet. B Neuropsychiatr. Genet., 174, 5, 10.1002/ajmg.b.32499 · DOI
  5. Cataldo, 2000, Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations, Am. J. Pathol., 157, 277, 10.1016/S0002-9440(10)64538-5 · DOI · Paper page
  6. Chi, 2015, Biogenesis of endosome-derived transport carriers, Cell. Mol. Life Sci., 72, 3441, 10.1007/s00018-015-1935-x · DOI
  7. Pfeffer, 2013, A nexus for receptor recycling, Nat. Cell Biol., 15, 446, 10.1038/ncb2751 · DOI
  8. De Strooper, 2007, Loss-of-function presenilin mutations in Alzheimer disease: Talking point on the role of presenilin mutations in Alzheimer disease, EMBO Rep., 8, 141, 10.1038/sj.embor.7400897 · DOI
  9. Li, 2016, Effect of presenilin mutations on APP cleavage; insights into the pathogenesis of FAD, Front. Aging Neurosci., 8, 51, 10.3389/fnagi.2016.00051 · DOI
  10. Woodruff, 2013, The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells, Cell Rep., 5, 974, 10.1016/j.celrep.2013.10.018 · DOI · Paper page
  11. Mattsson, 2016, Increased amyloidogenic APP processing in APOE varepsilon4-negative individuals with cerebral beta-amyloidosis, Nat. Commun., 7, 10918, 10.1038/ncomms10918 · DOI
  12. Small, 2006, Sorting through the cell biology of Alzheimer’s disease: intracellular pathways to pathogenesis, Neuron, 52, 15, 10.1016/j.neuron.2006.09.001 · DOI
  13. Kaether, 2006, Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface, Traffic, 7, 408, 10.1111/j.1600-0854.2006.00396.x · DOI
  14. Sannerud, 2016, Restricted location of PSEN2/gamma-secretase determines substrate specificity and generates an intracellular abeta pool, Cell, 166, 193, 10.1016/j.cell.2016.05.020 · DOI · Paper page
  15. Cataldo, 2004, Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome, Neurobiol. Aging, 25, 1263, 10.1016/j.neurobiolaging.2004.02.027 · DOI · Paper page
  16. Jiang, 2010, Alzheimer’s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition, Proc. Natl. Acad. Sci. U. S. A., 107, 1630, 10.1073/pnas.0908953107 · DOI
  17. Xu, 2016, Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration, J. Clin. Invest., 126, 1815, 10.1172/JCI82409 · DOI
  18. Vardarajan, 2015, Coding mutations in SORL1 and Alzheimer disease, Ann. Neurol., 77, 215, 10.1002/ana.24305 · DOI · Paper page
  19. Verheijen, 2016, A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease, Acta Neuropathol., 132, 213, 10.1007/s00401-016-1566-9 · DOI · Paper page
  20. Pottier, 2012, High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease, Mol. Psychiatry, 17, 875, 10.1038/mp.2012.15 · DOI · Paper page
  21. Holstege, 2017, Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy, Eur. J. Hum. Genet., 25, 973, 10.1038/ejhg.2017.87 · DOI · Paper page
  22. Rogaeva, 2007, The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease, Nat. Genet., 39, 168, 10.1038/ng1943 · DOI · Paper page
  23. Small, 2005, Model-guided microarray implicates the retromer complex in Alzheimer’s disease, Ann. Neurol., 58, 909, 10.1002/ana.20667 · DOI · Paper page
  24. Small, 2015, Retromer in Alzheimer disease, Parkinson disease and other neurological disorders, Nat. Rev. Neurosci., 16, 126, 10.1038/nrn3896 · DOI · Paper page
  25. Dumanis, 2015, Distinct functions for anterograde and retrograde sorting of SORLA in amyloidogenic processes in the brain, J. Neurosci., 35, 12703, 10.1523/JNEUROSCI.0427-15.2015 · DOI
  26. Pant, 2009, AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling, Nat. Cell Biol., 11, 1399, 10.1038/ncb1986 · DOI · Paper page
  27. Cormont, 2003, CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl, Traffic, 4, 97, 10.1034/j.1600-0854.2003.40205.x · DOI
  28. Xu, 2015, The role of PICALM in Alzheimer’s disease​, Mol. Neurobiol., 52, 399, 10.1007/s12035-014-8878-3 · DOI
  29. Matsudaira, 2015, Transport of the cholera toxin B-subunit from recycling endosomes to the Golgi requires clathrin and AP-1, J. Cell Sci., 128, 3131, 10.1242/jcs.172171 · DOI · Paper page
  30. Petralia, 2007, AP180 and CALM in the developing hippocampus: expression at the nascent synapse and localization to trafficking organelles, J. Comp. Neurol., 504, 314, 10.1002/cne.21454 · DOI
  31. Bhalla, 2012, The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport, Neurobiol. Dis., 47, 126, 10.1016/j.nbd.2012.03.030 · DOI · Paper page
  32. Offe, 2006, The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments, J. Neurosci., 26, 1596, 10.1523/JNEUROSCI.4946-05.2006 · DOI · Paper page
  33. Fjorback, 2012, Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing, J. Neurosci., 32, 1467, 10.1523/JNEUROSCI.2272-11.2012 · DOI · Paper page
  34. Ubelmann, 2017, Bin1 and CD2AP polarise the endocytic generation of beta-amyloid, EMBO Rep., 18, 102, 10.15252/embr.201642738 · DOI · Paper page
  35. Andersen, 2005, Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein, Proc. Natl. Acad. Sci. U. S. A., 102, 13461, 10.1073/pnas.0503689102 · DOI · Paper page
  36. Thomas, 2016, Decreasing the expression of PICALM reduces endocytosis and the activity of beta-secretase: implications for Alzheimer’s disease, BMC Neurosci., 17, 50, 10.1186/s12868-016-0288-1 · DOI · Paper page
  37. Xiao, 2012, Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis, J. Biol. Chem., 287, 21279, 10.1074/jbc.M111.338376 · DOI · Paper page
  38. Caglayan, 2014, Lysosomal sorting of amyloid-beta by the SORLA receptor is impaired by a familial Alzheimer’s disease mutation, Sci. Transl. Med., 6, 10.1126/scitranslmed.3007747 · DOI · Paper page
  39. Morabito, 2014, Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer’s disease, Neurobiol. Dis., 65, 188, 10.1016/j.nbd.2013.12.017 · DOI
  40. Colonna, 2016, TREM2 variants: new keys to decipher Alzheimer disease pathogenesis, Nat. Rev. Neurosci., 17, 201, 10.1038/nrn.2016.7 · DOI · Paper page
  41. Kim, 1998, A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E, J. Biochem., 124, 1072, 10.1093/oxfordjournals.jbchem.a022223 · DOI · Paper page
  42. Dafnis, 2016, The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific, Sci. Rep., 6, 30654, 10.1038/srep30654 · DOI · Paper page
  43. McColl, 2003, Endocytic pathway alterations in human hippocampus after global ischemia and the influence of APOE genotype, Am. J. Pathol., 162, 273, 10.1016/S0002-9440(10)63818-7 · DOI
  44. Heeren, 2004, Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation, J. Biol. Chem., 279, 55483, 10.1074/jbc.M409324200 · DOI · Paper page
  45. Heeren, 2006, Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 26, 442, 10.1161/01.ATV.0000201282.64751.47 · DOI · Paper page
  46. Chen, 2010, ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling, Proc. Natl. Acad. Sci. U. S. A., 107, 12011, 10.1073/pnas.0914984107 · DOI · Paper page
  47. DeKroon, 2001, The endosomal trafficking of apolipoprotein E3 and E4 in cultured human brain neurons and astrocytes, Neurobiol. Dis., 8, 78, 10.1006/nbdi.2000.0362 · DOI
  48. Ye, 2005, Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target, Proc. Natl. Acad. Sci. U. S. A., 102, 18700, 10.1073/pnas.0508693102 · DOI · Paper page
  49. Marquer, 2014, Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer’s disease early phenotypes, Mol. Neurodegener., 9, 60, 10.1186/1750-1326-9-60 · DOI
  50. Jin, 2004, Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities, Am. J. Pathol., 164, 975, 10.1016/S0002-9440(10)63185-9 · DOI
  51. Yasuda, 1995, Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer’s disease pathology: a biochemical study, Brain Res., 678, 161, 10.1016/0006-8993(95)00178-S · DOI · Paper page
  52. Hsieh, 2006, AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss, Neuron, 52, 831, 10.1016/j.neuron.2006.10.035 · DOI · Paper page
  53. Ehlers, 2000, Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting, Neuron, 28, 511, 10.1016/S0896-6273(00)00129-X · DOI · Paper page
  54. Choy, 2014, Retromer mediates a discrete route of local membrane delivery to dendrites, Neuron, 82, 55, 10.1016/j.neuron.2014.02.018 · DOI · Paper page
  55. Rajendran, 2006, Alzheimer’s disease beta-amyloid peptides are released in association with exosomes, Proc. Natl. Acad. Sci. U. S. A., 103, 11172, 10.1073/pnas.0603838103 · DOI · Paper page
  56. Polanco, 2016, Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner, J. Biol. Chem., 291, 12445, 10.1074/jbc.M115.709485 · DOI
  57. Perez-Gonzalez, 2012, The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space, J. Biol. Chem., 287, 43108, 10.1074/jbc.M112.404467 · DOI
  58. Sharples, 2008, Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes, FASEB J., 22, 1469, 10.1096/fj.07-9357com · DOI
  59. Sullivan, 2011, Retromer disruption promotes amyloidogenic APP processing, Neurobiol. Dis., 43, 338, 10.1016/j.nbd.2011.04.002 · DOI
  60. Calafate, 2016, Loss of bin1 promotes the propagation of tau pathology, Cell Rep., 17, 931, 10.1016/j.celrep.2016.09.063 · DOI · Paper page
  61. Chapuis, 2013, Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology, Mol. Psychiatry, 18, 1225, 10.1038/mp.2013.1 · DOI · Paper page
  62. Zhou, 2014, Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer’s disease, PLoS One, 9
  63. Yin, 2016, Vps35-dependent recycling of Trem2 regulates microglial function, Traffic, 17, 1286, 10.1111/tra.12451 · DOI · Paper page
  64. Altmann, 2015, Regional brain hypometabolism is unrelated to regional amyloid plaque burden, Brain, 138, 3734, 10.1093/brain/awv278 · DOI
  65. Bischof, 2016, Impact of tau and amyloid burden on glucose metabolism in Alzheimer’s disease, Ann. Clin. Transl. Neurol., 3, 934, 10.1002/acn3.339 · DOI
  66. Mullard, 2017, BACE inhibitor bust in Alzheimer trial, Nat. Rev. Drug Discov., 16, 155
  67. Mecozzi, 2014, Pharmacological chaperones stabilize retromer to limit APP processing, Nat. Chem. Biol., 10, 443, 10.1038/nchembio.1508 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Small, S. A., Simoes-Spassov, S., Mayeux, R., & Petsko, G. A.
Venue
Trends in Neurosciences
Publisher
Elsevier BV
Published
2017-10
Volume
40
Issue
10
Pages
592-602
ISSN
0166-2236
DOI
10.1016/j.tins.2017.08.003
PMC
PMC5654621
Cited by
168
References
21
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
NIH (AG034618, AG035015)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review